GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Ending Cash Position

Pharmala Biotech Holdings (XCNQ:MDMA) Ending Cash Position : C$0.27 Mil (As of Feb. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Ending Cash Position?

Pharmala Biotech Holdings's Ending Cash Position for the quarter that ended in Feb. 2025 was C$0.27 Mil.

Pharmala Biotech Holdings's quarterly Ending Cash Position increased from Aug. 2024 (C$0.00 Mil) to Nov. 2024 (C$0.20 Mil) and increased from Nov. 2024 (C$0.20 Mil) to Feb. 2025 (C$0.27 Mil).

Pharmala Biotech Holdings's annual Ending Cash Position declined from Aug. 2022 (C$0.85 Mil) to Aug. 2023 (C$0.20 Mil) but then increased from Aug. 2023 (C$0.20 Mil) to Aug. 2024 (C$0.42 Mil).


Pharmala Biotech Holdings Ending Cash Position Historical Data

The historical data trend for Pharmala Biotech Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Ending Cash Position Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Ending Cash Position
2.47 0.85 0.20 0.42

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24 Feb25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.04 - 0.20 0.27

Pharmala Biotech Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pharmala Biotech Holdings's Ending Cash Position for the fiscal year that ended in Aug. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.194+0.225
=0.42

Pharmala Biotech Holdings's Ending Cash Position for the quarter that ended in Feb. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.199+0.066
=0.27


Pharmala Biotech Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.
Executives
Fraser Macdonald Director
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer

Pharmala Biotech Holdings Headlines

No Headlines